13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001697013
Total reported value
$1.9B
$1.9B
85 檔
26.3%
During the Q3 2025 filing period, Eversept Partners, LP (CIK: 0001697013) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $1.9B across 85 reported positions.
In Q3 2025, Eversept Partners, LP displayed an active expansion posture, initiating 44 new positions and adding to 22 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | QQQ | Invesco Qqq Trust Series 1 | ETF-Tech | 9.52% | -3.49% | +33.57% | |
| 2 | UTHR | United Therapeutics CORP | Stock-Healthcare | 7.78% | -0.17% | +353.83% | |
| 3 | GSK | Gsk Plc-spon Adr | Stock-Healthcare | 6.31% | -3.89% | -5.44% | |
| 4 | NTRA | Natera Inc | Stock-Healthcare | 5.76% | -1.58% | -34.75% | |
| 5 | VERA | Vera Therapeutics Inc | Stock-Other | 5.62% | +0.32% | +17.83% | |
| 6 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 3.68% | -0.38% | -14.71% | |
| 7 | PCVX | Vaxcyte Inc | Stock-Other | 3.53% | -0.93% | +9.51% | |
| 8 | QURE | uniQure N.V. | Stock-Other | 3.53% | — | — | |
| 9 | HCA | Hca Healthcare Inc | Stock-Healthcare | 3.28% | +0.01% | +11.72% | |
| 10 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.86% | +0.05% | +1.14% | |
| 11 | ZIMV | Zimvie Inc | Stock-Other | 2.71% | — | — | |
| 12 | ABVX | Abivax Sa-adr | Stock-Other | 2.50% | +0.83% | — | |
| 13 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 2.43% | +0.23% | -8.53% | |
| 14 | RVTY | Revvity Inc | Stock-Healthcare | 2.38% | +0.09% | -22.73% | |
| 15 | TVTX | Travere Therapeutics Inc | Stock-Other | 2.33% | +1.50% | +7.77% | |
| 16 | TECH | Bio-techne CORP | Stock-Healthcare | 2.27% | -0.28% | +50.08% | |
| 17 | CLDX | Celldex Therapeutics Inc | Stock-Other | 2.06% | +0.46% | +37.58% | |
| 18 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 1.90% | — | +29.52% | |
| 19 | BRKR | Bruker CORP | Stock-Healthcare | 1.54% | +0.35% | -18.13% | |
| 20 | CYH | Community Health Systems Inc | Stock-Other | 1.54% | +0.01% | +13.11% | |
| 21 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 1.49% | +0.53% | +3.43% | |
| 22 | DHR | Danaher CORP | Stock-Healthcare | 1.36% | — | +323.36% | |
| 23 | GERN | Geron CORP | Stock-Other | 1.19% | -0.24% | +72.11% | |
| 24 | ELV | Elevance Health Inc | Stock-Healthcare | 1.00% | — | +137.21% | |
| 25 | PODD | Insulet CORP | Stock-Healthcare | 0.97% | -0.41% | — | |
| 26 | RGEN | Repligen CORP | Stock-Healthcare | 0.97% | -0.65% | +464.38% | |
| 27 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.96% | — | +17.89% | |
| 28 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.91% | — | — | |
| 29 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 0.83% | +0.42% | NEW | |
| 30 | ILMN | Illumina Inc | Stock-Healthcare | 0.81% | — | -37.72% | |
| 31 | AVTR | Avantor Inc | Stock-Healthcare | 0.80% | -1.23% | EXIT | |
| 32 | LQDA | Liquidia CORP | Stock-Other | 0.76% | +0.42% | +35.45% | |
| 33 | MNKD | Mannkind CORP | Stock-Other | 0.76% | — | +192.78% | |
| 34 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 0.72% | -0.56% | +13.74% | |
| 35 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 0.68% | +0.10% | — | |
| 36 | ICLR | ICON Public Limited Company | Stock-Healthcare | 0.66% | -0.40% | EXIT | |
| 37 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 0.65% | — | +26.15% | |
| 38 | EOLS | Evolus Inc | Stock-Other | 0.62% | — | +26.04% | |
| 39 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.56% | — | +27.88% | |
| 40 | CNC | Centene CORP | Stock-Healthcare | 0.55% | -0.19% | EXIT | |
| 41 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 0.55% | +0.12% | — | |
| 42 | ARDX | Ardelyx Inc | Stock-Other | 0.54% | -0.26% | — | |
| 43 | BIIB | Biogen Inc | Stock-Healthcare | 0.50% | — | — | |
| 44 | CPRX | Catalyst Pharmaceuticals Inc | Stock-Healthcare | 0.48% | — | — | |
| 45 | DVAX | Dynavax Technologies CORP | Stock-Other | 0.47% | — | -42.07% | |
| 46 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 0.44% | -0.12% | — | |
| 47 | ETNBGBP | 89bio Inc | Stock-Other | 0.40% | — | +66.30% | |
| 48 | HQY | Healthequity Inc | Stock-Healthcare | 0.34% | -0.23% | EXIT | |
| 49 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.32% | +0.20% | +67.50% | |
| 50 | ✓ | Merus N V | Stock-Other | 0.31% | — | -63.30% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | UTHR | United Therapeutics CORP | +6% | +353.83% | Add |
| 2 | QQQ | Invesco Qqq Trust Series 1 | +2.5% | +33.57% | Add |
| 3 | PCVX | Vaxcyte Inc | +1.4% | +9.51% | Add |
| 4 | VERA | Vera Therapeutics Inc | +1% | +17.83% | Add |
| 5 | VRDN | Viridian Therapeutics Inc | +1% | +1.14% | Add |
| 6 | IONS | Ionis Pharmaceuticals Inc | +0.9% | -8.53% | Add |
| 7 | TVTX | Travere Therapeutics Inc | +0.8% | +7.77% | Add |
| 8 | CLDX | Celldex Therapeutics Inc | +0.8% | +37.58% | Add |
| 9 | RGEN | Repligen CORP | +0.7% | +464.38% | Add |
| 10 | TECH | Bio-techne CORP | +0.6% | +50.08% | Add |
| 11 | AVTR | Avantor Inc | +0.6% | -39.43% | Add |
| 12 | LQDA | Liquidia CORP | +0.5% | +35.45% | Add |
| 13 | ICLR | ICON Public Limited Company | +0.5% | -14.80% | Add |
| 14 | ZIMV | Zimvie Inc | +0.4% | — | Unchanged |
| 15 | MNKD | Mannkind CORP | +0.4% | +192.78% | Add |
| 16 | NAMS | NewAmsterdam Pharma Company N.V. | +0.4% | +17.89% | Add |
| 17 | ELV | Elevance Health Inc | +0.3% | +137.21% | Add |
| 18 | ALEC | Alector Inc | +0.2% | -25.04% | Add |
| 19 | ETNBGBP | 89bio Inc | +0.2% | +66.30% | Add |
| 20 | ✓ | Merus N V | 0% | -63.30% | Trim |
| 21 | IFRX | InflaRx N.V. | 0% | +5.50% | Add |
| 22 | STRO | Sutro Biopharma, Inc. | 0% | -0.04% | Trim |
| 23 | EHTH | Ehealth Inc | 0% | — | Add |
| 24 | FTRE | Fortrea Holdings Inc | -0.1% | — | Trim |
| 25 | NVAX | Novavax Inc | -0.1% | — | Trim |
| 26 | ZBIO | Zenas Biopharma Inc | -0.1% | -51.23% | Trim |
| 27 | MRVI | Maravai Lifesciences Hldgs-a | -0.2% | -54.63% | Trim |
| 28 | GOSS | Gossamer Bio Inc | -0.3% | -45.44% | Trim |
| 29 | TEVA | Teva Pharmaceutical-sp Adr | -0.3% | +29.52% | Trim |
| 30 | HUM | Humana Inc | -0.5% | -61.82% | Trim |
| 31 | BRKR | Bruker CORP | -0.6% | -18.13% | Add |
| 32 | MOH | Molina Healthcare Inc | -0.7% | -54.03% | Trim |
| 33 | CYH | Community Health Systems Inc | -0.8% | +13.11% | Trim |
| 34 | RVTY | Revvity Inc | -0.8% | -22.73% | Add |
| 35 | BCRX | Biocryst Pharmaceuticals Inc | -0.9% | +13.74% | Trim |
| 36 | CNC | Centene CORP | -1.6% | -43.68% | Trim |
| 37 | SNDX | Syndax Pharmaceuticals Inc | -1.6% | -14.71% | Trim |
| 38 | HCA | Hca Healthcare Inc | -2.1% | +11.72% | Trim |
| 39 | HQY | Healthequity Inc | -2.8% | -66.39% | Trim |
| 40 | GSK | Gsk Plc-spon Adr | -4% | -5.44% | Trim |
| 41 | NTRA | Natera Inc | -7.1% | -34.75% | Trim |
| 42 | QURE | uniQure N.V. | — | NEW | New buy |
| 43 | SPY | Ss Spdr S&p 500 ETF Trust-us | — | EXIT | Sold out |
| 44 | ABVX | Abivax Sa-adr | — | NEW | New buy |
| 45 | INSP | Inspire Medical Systems Inc | — | EXIT | Sold out |
| 46 | PTGX | Protagonist Therapeutics Inc | — | EXIT | Sold out |
| 47 | UNH | Unitedhealth Group Inc | — | NEW | New buy |
| 48 | DHR | Danaher CORP | — | NEW | New buy |
| 49 | NBIX | Neurocrine Biosciences Inc | — | EXIT | Sold out |
| 50 | GERN | Geron CORP | — | NEW | New buy |
According to official SEC Form 13F filings, Eversept Partners, LP reported a total U.S. public equity portfolio value of $1.9B across 85 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including QQQ, UTHR, GSK) accounted for 26.3% of total reported equity market value during Q3 2025.
Top New Position Initiated
QURE
市值: $51.2M
Top Position Liquidated / Trimmed
SPY
前期市值: $43.0M
During Q3 2025, Eversept Partners, LP's top holdings by market value included QQQ (9.5%)、UTHR (7.8%)、GSK (6.3%). The largest single position, QQQ, represented 9.5% of total portfolio value.
In Q3 2025, Eversept Partners, LP made 99 total portfolio adjustments, initiating 44 new buys, adding to 22 positions, trimming 18 holdings, and fully liquidating 15 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.